Skip to main content
OpenTrials
Completed

NCT Number: NCT05198895

Safety and Performance of the Glyconics-SX System

The main clinical study objective is to retrieve initial high quality spectra measurements indicative of the accuracy of the Glyconics-SX System in distinguishing between individuals with or without T2DM based on known and/or assumed clinical status of the participants and as controlled by values of an internal biomarker indicative of glycaemia, HbA1c, as measured with validated, comparator device.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Leicester Diabetes Centre

Leicester, United Kingdom

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Apparently healthy adults (≥18 years of age) with known or unknown T2DM status willing to participate in and provide a written consent for the study
  • willingness to undertake assisted assessment of glycaemia by both the NIR spectra measurement, and HbA1c by finger prick test
  • Individuals with two visually assessed apparently healthy, undamaged, and intact fingernails, one in both right- and left-hand middle fingers

Exclusion criteria

  • Individuals with any known medical conditions impacting either of the assessment methodology for glycaemia, such as
  • anaemia (iron deficiency sickle cell anaemia or similar)
  • haemoglobinopathies or atypical haemoglobin subtypes not detectable by regular assays,
  • severe renal impairment (CKD stage III-IV) or decompensated hepatic disease
  • severe Vitamin D deficiency
  • known severe immunodeficiency such as HIV, malignancy or other chronic condition significantly impacting assessment of glycaemia
  • eating disorders (as per clinical assessment)
  • Recent (within 28 days) blood donation
  • Any structural, deviating and visually detectable deviations in the appearance of the nails potentially impacting the spectra measurement, including
  • nail dystrophy or deformity
  • severe nail infections (onychomycosis causing visual changes in the appearance of the nail)
  • rare hereditable conditions impacting the structure of keratin
  • mechanical damage or marks on the surface of the nail after removal of nail polish
  • use of acrylic or gel nail decoration and polish, which cannot be removed
  • Any systemic or topical medication known to modify either the surface or structure of the nail or accuracy of HbA1c value.

Treatment and study plan

Near-infrared (NIR)

Device

NIR spectral assessment of glycated nail keratin vs glycated haemoglobin (HbA1c)

Other names: point-of-care device (HbA1c analyser)

Primary outcomes

  1. Accuracy of the Glyconics-SX System in detection of DM status based on dichotomised outcomes as per the chemometric model (HbA1c measurements as internal control)

    Time frame: 60 seconds

    Overall probability of correct classification by the chemometric model output (yes / no DM)

Secondary outcomes

  1. Assessment of sensitivity and specificity for chemometric model outcomes

    Time frame: 60 seconds

    False positive and false negative assessments in %

  2. Calculation of negative and positive predictive value for the chemometric model

    Time frame: 60 seconds

    Calculated values in %

  3. Calculation of area under the curve (AUC) with axis defined by false positive and negative rates (FPR, FNR) for the chemometric model

    Time frame: 60 seconds

    Area under the curve value

  4. Median (IQR) HbA1c values in both groups (with or without diabetes) as measured by the comparative device

    Time frame: 4 minutes

    HbA1c value in mmol/mol

  5. Analysis of safety outcomes (AEs, SAEs), including any safety outcomes listed in the comments, such as potential, suspected de novo diabetes diagnosis cases based on HbA1c readings

    Time frame: 15 minutes

    Adverse events

Sponsors and collaborators

Lead sponsor

Glyconics Ltd

Industry

Registry information

Official study title

A Single-centre, Open-label Study Testing the Safety and Performance of the Glyconics-SX System in Individuals With or Without Type 2 Diabetes

Acronym: ANODE01

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Jan 20, 2022
Registry last updated
Oct 23, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.